{
    "clinical_study": {
        "@rank": "94094", 
        "arm_group": [
            {
                "arm_group_label": "acamprosate", 
                "arm_group_type": "Active Comparator", 
                "description": "The maximum dose of acamprosate to be used in this study is 666 mg three times daily (total 1998 mg/day) for subjects weight \u2265 50 kg and 1332mg for subjects that weigh < 50 kg."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be prescribed with the same frequency and duration as the acamprosate group."
            }
        ], 
        "brief_summary": {
            "textblock": "In this research study we want to understand the effectiveness of a drug treatment,\n      acamprosate, for interfering symptoms (i.e., inattention/hyperactivity, social impairment)\n      associated with Fragile X Syndrome (FXS)."
        }, 
        "brief_title": "Study of Acamprosate in Fragile x Syndrome", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Fragile X Syndrome", 
        "condition_browse": {
            "mesh_term": "Fragile X Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnostic confirmation of full mutation FXS\n\n          -  Age \u22655 years and <23 years\n\n          -  General good health as determined by physical exam, medical history and laboratory\n             work up.\n\n        Exclusion Criteria:\n\n          -  Use of more than two psychotropic medications (medications affecting behavior).\n\n          -  Unstable dosing of any psychotropic medication (medication affecting behavior)\n\n          -  Problems with kidney functioning\n\n          -  Unstable seizure disorder\n\n          -  Change in any anti-convulsant drug dosing in the 60 days prior to study entry\n\n          -  Prior adequate treatment trial with acamprosate as determined by the study doctor\n\n          -  Pregnant or lactating females"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "23 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911455", 
            "org_study_id": "CIN001- Acamprosate in FX"
        }, 
        "intervention": [
            {
                "arm_group_label": "acamprosate", 
                "intervention_name": "acamprosate", 
                "intervention_type": "Drug", 
                "other_name": "Campral"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Acamprosate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Fragile X Syndrome", 
        "lastchanged_date": "March 5, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jamie_a_chin@rush.edu", 
                    "last_name": "Jamie Chin", 
                    "phone": "312-942-0025"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Elizabeth Berry-Kravis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fragilex@cchmc.org", 
                    "last_name": "Katie Friedmann, RN", 
                    "phone": "513-636-0523"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "Cincinnati Children's Hospital Medical Center"
                }, 
                "investigator": {
                    "last_name": "Craig Erickson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome", 
        "overall_contact": {
            "email": "fragilex@cchmc.org", 
            "last_name": "Katie Friedmann, RN", 
            "phone": "513-636-0523"
        }, 
        "overall_official": [
            {
                "affiliation": "Children's Hospital Medical Center, Cincinnati", 
                "last_name": "Craig Erickson, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Rush University Medical Center", 
                "last_name": "Elizabeth Berry-Kravis, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Aberrant Behavior Checklist-Social Withdrawal subscale", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline to week 10"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical Global Impressions- Improvement (CGI-I)", 
                "safety_issue": "No", 
                "time_frame": "week 10"
            }, 
            {
                "measure": "Aberrant Behavior Checklist- Hyperactivity (ABC-H)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to week 10"
            }, 
            {
                "measure": "Aberrant Behavior Checklist-Social Avoidance (ABC-SA)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to week 10"
            }
        ], 
        "source": "Children's Hospital Medical Center, Cincinnati", 
        "sponsors": {
            "collaborator": {
                "agency": "Rush University Medical Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Children's Hospital Medical Center, Cincinnati", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}